Market capitalization | $809.46m |
Enterprise Value | $791.87m |
P/E (TTM) P/E ratio | 64.50 |
EV/FCF (TTM) EV/FCF | 28.61 |
EV/Sales (TTM) EV/Sales | 4.36 |
P/S ratio (TTM) P/S ratio | 4.46 |
P/B ratio (TTM) P/B ratio | 3.39 |
Dividend yield | 1.89% |
Last dividend (FY23) | $8.70 |
As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.
1 Analyst has issued a forecast Atrion Corporation:
1 Analyst has issued a forecast Atrion Corporation:
Jun '24 |
+/-
%
|
||
Revenue | 182 182 |
6%
6%
|
|
Gross Profit | 58 58 |
15%
15%
|
|
EBITDA | 30 30 |
32%
32%
|
EBIT (Operating Income) EBIT | 14 14 |
52%
52%
|
Net Profit | 13 13 |
54%
54%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Atrion Corp. engages in the manufacture and development of products for medical applications. It offers products fro cardiovascular, fluid delivery, and ophthalmic. It also offers contract manufacturing and kitting services; and marine and aviation inflation components. The company was founded in 1944 and is headquartered in Allen, TX.
Head office | United States |
CEO | David Battat |
Employees | 712 |
Founded | 1944 |
Website | www.atrioncorp.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.